Research. Advocacy. Support.

Latest News

• USPSTF Does Not Recommend Ovarian Cancer Screening for General Population

  (July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing… More

  Posted Jul 19, 2017

• OCRFA Earns 4-Star Rating from Charity Navigator

  (July 6, 2017) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This rating, the highest awarded by Charity Navigator, demonstrates OCRFA’s continued commitment to maintaining responsible fiscal management practices, as well as transparency and accountability, as we continue to strive toward a cure for ovarian… More

  Posted Jul 6, 2017

• Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients

  (July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.

  Posted Jul 6, 2017